Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the tre... Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). Show more
GAITHERSBURG, Md., Sept. 10, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Altimmune, Inc. (Nasdaq:ALT), please note that the reduction of visceral...
Lean Loss Ratio of only 21.9%, representing class-leading preservation of lean mass Maintenance of lean mass preservation in individuals over the age of 60, a population at risk for...
GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the data from its Phase 2, MRI-based body...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.5401 | 7.8049132948 | 6.92 | 8.25 | 6.74 | 3065991 | 7.53068086 | CS |
4 | 0.3601 | 5.07183098592 | 7.1 | 8.25 | 5.99 | 2247387 | 6.9837263 | CS |
12 | 0.2101 | 2.89793103448 | 7.25 | 8.26 | 5.275 | 2741367 | 6.76959292 | CS |
26 | -2.2699 | -23.3288797533 | 9.73 | 11.01 | 5.275 | 3180533 | 7.33487896 | CS |
52 | 4.5401 | 155.482876712 | 2.92 | 14.84 | 2.09 | 5213598 | 7.59537415 | CS |
156 | -7.4799 | -50.0662650602 | 14.94 | 23.49 | 2.09 | 2749340 | 8.26686241 | CS |
260 | 5.2801 | 242.206422018 | 2.18 | 35.1 | 1.45 | 2362306 | 9.80045968 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.